• Icure Pharmaceutical filed a correction to a large-shareholding report, citing a clerical error in prior summary disclosures.
• Previous report restated at 24,287,115 shares, 39.34% ownership; shares tied to key contracts restated at 24,177,949, 39.16%.
• Latest filing shows holdings rising to 24,739,115 shares, 40.07%, driven by adding a special related party.
• Change reflects inclusion of shares held by an existing outside director, adding 452,000 shares, 0.73% based on Sept. 30.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Icure Pharmaceutical Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261007000398), on October 07, 2026, and is solely responsible for the information contained therein.